Y-mAbs Therapeutics (NASDAQ:YMAB) Receives New Coverage from Analysts at BMO Capital Markets

Stock analysts at BMO Capital Markets began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) in a research report issued on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.

Several other equities research analysts have also commented on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, April 29th. Wedbush reduced their price target on shares of Y-mAbs Therapeutics from $28.00 to $21.00 and set an “outperform” rating for the company in a research report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.60.

NASDAQ:YMAB traded up $0.79 during mid-day trading on Thursday, reaching $14.67. The company’s stock had a trading volume of 11,943 shares, compared to its average volume of 445,359. Y-mAbs Therapeutics has a 12-month low of $6.50 and a 12-month high of $39.82. The firm’s fifty day moving average price is $11.03 and its two-hundred day moving average price is $11.63. The stock has a market cap of $641.23 million, a P/E ratio of -5.47 and a beta of 1.44.

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) last released its quarterly earnings results on Monday, May 9th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.10. Y-mAbs Therapeutics had a negative net margin of 291.89% and a negative return on equity of 59.67%. The firm had revenue of $10.49 million during the quarter, compared to analyst estimates of $11.10 million. During the same quarter in the prior year, the firm earned $0.75 EPS. The business’s revenue for the quarter was up 94.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Y-mAbs Therapeutics will post -1.7 EPS for the current year.

Several large investors have recently made changes to their positions in the stock. DNB Asset Management AS grew its stake in shares of Y-mAbs Therapeutics by 6.4% during the 4th quarter. DNB Asset Management AS now owns 13,367 shares of the company’s stock valued at $217,000 after acquiring an additional 801 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of Y-mAbs Therapeutics during the 3rd quarter valued at approximately $28,000. DekaBank Deutsche Girozentrale boosted its stake in Y-mAbs Therapeutics by 9.9% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,400 shares of the company’s stock worth $172,000 after purchasing an additional 1,300 shares during the period. Credit Suisse AG boosted its stake in Y-mAbs Therapeutics by 8.8% in the 3rd quarter. Credit Suisse AG now owns 16,942 shares of the company’s stock worth $483,000 after purchasing an additional 1,375 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $49,000. Institutional investors own 60.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile (Get Rating)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Featured Articles